Optimal variants of treatment of stage I endometrial carcinoma and its choice.
2195 patients affected by endometrial carcinoma were treated at the Tbilisi and the St. Petersburg Oncological Institutes from 1968 to 1987. The incidence of different stages was respectively: I 78.8%; II 11.6%; III 9.0%; IV 0.4%. Adenocarcinoma was the histotype more frequently observed and the grade of differentiation was respectively: G1 39.3%; G2 51.3%; G3 9.4%. The incidence of lymphnodal invasion was equal to 6.2% in I Stage, 12.2% in II Stage and 37.8% in III Stage. In Stage I surgery was the treatment of choice in all cases and in the 70.5% of cases additional treatments were added: in G1, G2 grade endometrial cancer additional hormone therapy, remote irradiation and postoperative hormone therapy were used, whereas in G3 tumours intracavitary irradiation was frequently added in the St. Petersburg Institute. The 5 year survival rate of patients at Stage I was equal to 70.9% in retrospective analysis (1968-1982) and 84.6% in patients followed prospectively (1983-1987).
Charkviani
T L
TL
Institute Oncologic, Tbilisi, Georgia.
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use; D007044:Hysterectomy; D008197:Lymph Node Excision; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011446:Prospective Studies; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D006908:Hydroxyprogesterones; D000077713:17 alpha-Hydroxyprogesterone Caproate